Published on October 6, 2009 at 12:22 AM
Research and Markets (http://www.researchandmarkets.com/research/e40af4/the_top_40_develop) has announced the addition of the "The Top 40 Developers Of Inhaled Pharmaceuticals Worldwide" report to their offering.
Inhaled therapies have been used since ancient times and may have had their origins with the smoking of datura preparations in India 4,000 years ago. Inhalation became a mainstay of respiratory care in the 20th century. Due to the nature of the absorption within the lungs, inhaled pharmaceuticals tend to be very fast acting. Inhalation usually provides a very fast rise of the level of the pharmaceutical in the blood, when compared to other delivery techniques, such as oral or transdermal delivery. For example, albuterol is a bronchodialator which acts rapidly when inhaled to treat an asthma attack, a condition for which treatment with a solid oral dosage form may be too slow. In fact, inhaled medication is the commonest form of therapy for acute and chronic asthma and for other conditions associated with airflow limitation (obstructive bronchitis, emphysema, cystic fibrosis).
There are many pharmaceutical companies worldwide. This report profiles the Top 40 developers of inhaled pharmaceuticals. These are the companies with the experience, know-how and resources that enable them to develop, manufacture and market innovative products that can compete effectively in global markets.
Profile information for each company in The Top 40 Developers Of Inhaled Pharmaceuticals Worldwide typically includes:
- Company Contact Information - Address, Telephone and Fax Numbers, Email and Website Address
- Key Company Decision Makers - From CEO and Main Board, to Key Senior Managers
- Specialised fields such as Company Description, Ownership, Products, Therapeutic Areas, Foreign Trade, Location Status, Year Established, Number of Employees and Turnover.
http://www.researchandmarkets.com/research/e40af4/the_top_40_develop